Welcome to our dedicated page for TRIL news (Ticker: TRIL), a resource for investors and traders seeking the latest updates and insights on TRIL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRIL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRIL's position in the market.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced its inclusion in the Russell 2000® and 3000® Indices, effective June 28, 2021. This milestone follows a major turnaround in 2020 and the launch of an ambitious Phase 1b/2 program for its CD47-targeting therapies. The Russell indexes are significant benchmarks, with around $10.6 trillion in assets indexed, providing Trillium increased visibility among institutional investors. The company's lead programs include TTI-622 and TTI-621, aimed at enhancing cancer treatment by targeting immune evasion mechanisms.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced the results from its Annual General and Special Meeting held on June 8, 2021. Notable outcomes included the re-election of Mr. Luke Beshar, Dr. Michael Kamarck, and others as directors, with Beshar receiving 89.6% of votes in favor. Ernst & Young LLP was reappointed as auditors. Shareholders approved an advisory vote on executive compensation, suggesting annual reviews. The company focuses on developing therapies targeting cancer, particularly through its CD47 programs, TTI-622 and TTI-621.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) reported its financial results for Q1 2021, highlighting a cash position of $275.7 million, down from $291.2 million at the end of 2020. The net loss was $10.9 million, a decrease from $16.3 million year-over-year, attributed to lower non-cash losses in the previous period. Research and development expenses rose to $5.9 million from $5.0 million, driven by higher manufacturing and clinical trial costs. General and administrative expenses fell to $5.4 million from $11.7 million, mainly due to a prior period non-cash loss.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) has announced the successful dosing of the first patient with TTI-622, an investigational checkpoint inhibitor for multiple myeloma, in combination with carfilzomib and dexamethasone. This milestone initiates a Phase 1b/2 program targeting five indications and six patient settings. TTI-622 aims to block the "don't eat me" signal from CD47 on tumor cells, enhancing macrophage activity. The trial will evaluate safety and response rates in relapsed/refractory multiple myeloma patients, addressing significant unmet medical needs in this area.
Trillium Therapeutics (NASDAQ/TSX: TRIL) reports significant progress in its clinical trials for TTI-622 and TTI-621, demonstrating a 33% objective response rate in relapsed/refractory lymphomas for TTI-622 and an 18-29% response rate for TTI-621. Both drug candidates are well tolerated with no maximum tolerated dose reached. A Phase 1b/2 program has been initiated across seven indications, with multiple studies expected to commence in the next year. Governance changes include new Board member Scott Myers, with retirements of Robert Kirkman and Tom Reynolds. The company holds $276 million in cash to support ongoing trials.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced its virtual R&D Day scheduled for April 28, 2021, from 10:00 a.m. to 1:00 p.m. ET. The event will cover a clinical update on TTI-622 and TTI-621, new strategic priorities for drug combinations in hematologic malignancies and solid tumors, and updated milestones for 2021. Investors can access further information and the live webcast through Trillium's investor relations website. Trillium focuses on developing therapies that target the CD47 protein, aiding in cancer treatment.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced the completion of a comprehensive transformation program, marking 2020 as a pivotal year. Key highlights include a $25 million equity investment from Pfizer and advancements in CD47 clinical programs TTI-622 and TTI-621, aiming for Phase 2 studies in 2021. As of December 31, 2020, Trillium reported $291.2 million in cash and a net loss of $59.3 million, up from a loss of $38.1 million in 2019. A Research and Development Day is scheduled for April 28, 2021, to outline future strategic priorities.
Trillium Therapeutics (NASDAQ/TSX: TRIL) has received Notices of Allowance for two patent applications from the U.S. Patent and Trademark Office. These patents cover the use of SIRPaFc biologics, TTI-621 and TTI-622, to treat CD47+ cancers, including hematologic and solid tumors. The method of use patent has already been granted in Japan, Canada, and Australia, further solidifying Trillium’s position in the immuno-oncology space. CEO Jan Skvarka emphasized the importance of intellectual property in enhancing their competitive edge.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) appointed Michael Kamarck, Ph.D., to its Board of Directors, effective immediately. Dr. Kamarck brings over 25 years of pharmaceutical experience, including leadership roles in biologics manufacturing. His appointment comes as Trillium prepares to enhance its clinical development with multiple Phase 2 programs anticipated next year. Trillium is focused on innovative cancer therapies targeting CD47, with its pipeline showing potential for best-in-class treatments.
Trillium Therapeutics has successfully completed its public offering, selling 11,500,000 common shares at US$13.00 each, raising gross proceeds of US$149.5 million. The offering included the full exercise of underwriters' options for an additional 1,500,000 shares. The net proceeds will be utilized for ongoing clinical trials focusing on the CD47 program, alongside working capital and corporate needs. Trillium aims to swiftly advance its investigational program into multiple Phase 2 trials.
